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Hyponatremia is a common electrolyte disorder associated
with increased morbidity and mortality, particularly in the
elderly. Lixivaptan, a new selective vasopressin V2-receptor
antagonist, safely corrected serum sodium concentrations in
phase II studies of patients with euvolemic hyponatremia.
Here our multinational, double-blind, placebo-controlled,
phase III study assessed the effect of lixivaptan on serum
sodium concentrations in 106 initially hospitalized patients
with euvolemic hyponatremia (serum sodium less than
130mmol/l). Of them, 52 were randomized to receive
placebo and 54 received 50mg lixivaptan once daily and
were then titrated to receive 25–100mg once daily
depending on serum sodium concentration. Fluid restriction
was at the investigator’s discretion. Initial titration occurred
in a monitored inpatient setting; patients were then treated
as outpatients for a total of 30 days. The primary end point
was the change in serum sodium concentration from
baseline to day 7. Lixivaptan significantly increased the
serum sodium concentration from baseline to day 7 (the
primary end point) by 6.7mmol/l compared with placebo
(4.5mmol/l; P¼ 0.034). Importantly, the serum sodium
concentration was normalized safely and more rapidly in
patients receiving lixivaptan than placebo (P¼ 0.004) and
was well tolerated. After drug discontinuation, serum sodium
concentrations decreased to near-baseline levels within 7
days. Thus, lixivaptan safely and effectively corrects serum
sodium concentrations in patients with euvolemic
hyponatremia.
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Hyponatremia, defined as serum sodium concentration
o135mmol/l, is the most common electrolyte disorder
diagnosed in clinical practice.1,2 Various forms of hypona-
tremia have been described on the basis of fluid status.3
Hypovolemic hyponatremia, generally associated with salt
wasting, is often transient and may be managed with oral or
intravenous electrolyte replacement and/or using mineralo-
corticoids. Euvolemic hyponatremia is most commonly
associated with the syndrome of inappropriate antidiuretic
hormone (SIADH) secretion and is frequently of iatrogenic
origin. Idiopathic forms of euvolemic hyponatremia are also
observed more frequently in elderly patients. Hypervolemic
hyponatremia generally exists as a complication of persistent
underlying disease, such as cirrhosis or congestive heart
failure, with fluid excess manifesting as edema or ascites.
The incidence of hyponatremia is estimated to be as high as
30% in the hospitalized setting4 and 21% in ambulatory
patients.5 Importantly, the incidence of hyponatremia increases
with age and has been reported in up to 53% of elderly patients
in chronic care settings.2,6–8 Hyponatremia is associated with
complications of comorbid conditions,9 significantly greater
length of hospital stay,10 and higher readmission rates.11
Further, hyponatremia is a strong predictor of both inhospital
and postdischarge mortality. Inhospital mortality rates of 16%
have been reported in patients 465 years of age with
hyponatremia compared with 8% in those with normal
sodium concentrations on admission.12
Even mild ‘asymptomatic’ hyponatremia may be a mis-
nomer as patients with this condition often have unrecognized
neurological manifestations, including attention deficits, im-
pairment of balance, and falls.13–16 Further, hyponatremia can
lead to decreased bone mineral density with increasing bone
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fragility17,18 and has been shown to be a significant risk factor
for bone fracture, independent of osteoporosis.19 As a result of
this combination of neurologic impairment and decreased
bone mineral density, elderly patients with hyponatremia are
more susceptible to serious fractures with increased morbidity
and mortality.20,21 In addition, even in patients with mild
hyponatremia (130–134mmol/l), an increased risk for death
has been reported.22
Fluid restriction, a common first-line treatment for chronic
hyponatremia, is associated with poor tolerability. Pharmaco-
logic therapy has included demeclocycline, lithium carbonate,
and urea; however, side effects and nephrotoxicity limit the use
of demeclocycline and lithium carbonate, and lack of
availability and unpleasant taste limit the use of urea.23,24
Drug therapy that selectively antagonizes arginine vaso-
pressin’s action offers an ideal treatment modality for subjects
with hyponatremia. Vaptans, a new class of vasopressin-
receptor antagonists, increase free-water excretion, urine flow,
and serum osmolarity and decrease urine osmolality. Two
vaptans are currently approved in the United States:
conivaptan, an intravenous mixed V1a/V2-receptor antagonist,
and tolvaptan, an oral selective V2-receptor antagonist.25,26
Lixivaptan is a potent, selective, orally active vasopressin V2-
receptor antagonist. It has been shown in phase II studies to
increase serum sodium levels in subjects with hyponatremia
associated with SIADH,27 chronic heart failure,28 and cirrhosis.29
The objective of this phase III study (LIBRA) was to assess the
safety and efficacy of lixivaptan in achieving and maintaining an
increase in serum sodium concentration in hospitalized subjects
with SIADH or other conditions of euvolemic hyponatremia.
RESULTS
Subjects
Of 106 randomized subjects (lixivaptan, n¼ 54; placebo,
n¼ 52), 101 received treatment, and 73 completed both the
treatment period and follow-up periods of the study
(Figure 1). In both treatment arms, the most common
reason for discontinuation was withdrawal of consent.
Baseline characteristics of subjects who received the study
drug have been summarized in Table 1. Most subjects were
white and from North America or Western Europe. More
than half of the subjects were X65 years of age. Although
baseline characteristics were generally well balanced between
groups, significantly fewer subjects in the lixivaptan group
Randomized (N = 106)
Allocated to lixivaptan (n = 54) Allocated to placebo (n = 52)
Day 7 (primary end point)
Completed study (n = 34)
Not completing study (n = 17)
Adverse event (n = 4)
Death (n = 4)*
Lost to follow-up (n = 2)
Other (n = 2)
Excluded from analysis (n = 0)
Analyzed for primary efficacy
end point (n = 52)
Subject withdrew consent (n = 5)
Sodium values assessed in
45 subjects
Received placebo (n = 51)
Did not receive placebo (n = 1)
– Other (n = 1)
Received lixivaptan (n = 50)
Did not receive lixivaptan (n = 4)
– Subject withdrew consent (n = 2)
– Other (n = 2)
Day 7 (primary end point)
Completed study (n = 39)
Adverse event (n = 2) 
Lost to follow-up (n = 1)
Subject withdrew consent (n = 4)
Other (n = 3)
Excluded from analysis (n = 0)
Analyzed for primary efficacy
end point (n = 54)
Investigator withdrew patient (n = 1)
Not completing study (n = 11)
Sodium values assessed in 
47 subjects
Figure 1 | Subject disposition. *In the placebo group, two
subjects died during the treatment period and two subjects died
during the 30-day follow-up period.
Table 1 | Subject demographics and baseline characteristics
Demographic parameter Lixivaptan (n=54) Placebo (n=52)
Age, years
Mean (s.d.) 66.4 (14.1) 65.2 (13.3)
Range 38–87 29–87
Subjects aged X65 years, n (%) 32 (59) 26 (50)
Male subjects, n (%) 26 (48) 30 (58)
Race, n (%)
White 44 (82) 44 (85)
Asian 8 (15) 6 (12)
Black 2 (4) 2 (4)
Region, n (%)
North America 19 (35) 19 (37)
Western Europe 19 (35) 18 (35)
Eastern Europe 9 (17) 9 (17)
Asia 7 (13) 6 (12)
BMI, kg/m2 n=49 n=47
Mean (s.d.) 25.8 (4.5) 25.9 (6.4)
Range 18.5–37.6 16.6–46.2
Locala serum sodium, mmol/l
Mean (s.d.) 124.7 (5.2) 124.1 (5.4)
Range 105.0–129.2 108.7–129.0
Centralb serum sodium, mmol/l
Mean (s.d.) 127.6 (5.7) 126.1 (5.9)
Range 107–135 109–137
Serum creatinine, mg/dl n=51 n=49
Mean (s.d.) 0.740 (0.250) 0.730 (0.250)
Range 0.199–1.290 0.171–1.370
N (%) of subjects with history of:c
Hypertension 35 (65) 35 (67)
Type 2 diabetes mellitus 3 (6) 11 (21)
Constipation 9 (17) 11 (21)
Depression 9 (17) 11 (21)
Osteoarthritis 14 (26) 2 (4)
Osteoporosis 12 (22) 3 (6)
Abbreviation: BMI, body mass index.
aMeasured at local laboratories.
bMeasured at central laboratory.
cConditions reported by X20% of subjects in any group.
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were on fluid restriction at baseline compared with those in
the placebo group (20 (37.0%) vs. 34 (65.4%) subjects,
respectively; P¼ 0.004). Numerous symptoms of hyponatre-
mia were apparent at baseline, most commonly fatigue and
slowing of mental faculties (Figure 2). The underlying cause
of SIADH was not investigated prospectively in the study. At
baseline, eight patients (8.0%) had lung cancer, two (2.0%)
had human immunodeficiency virus infection, and 33 (33%)
were receiving drugs known to induce hyponatremia,
including carbamazepine (7.0%), cyclophosphamide (1.0%),
phenothiazines (2.0%), selective serotonin reuptake inhibi-
tors (10.0%), thiazides (6.0%), and monoamine oxidase
inhibitors (7.0%).
Efficacy
On day 7, the least-squared mean (LSM) ±s.e. change from
baseline in serum sodium concentration was 6.7±0.7mmol/l
in the lixivaptan group and 4.5±0.8mmol/l in the placebo
group (LSM±s.e. difference of 2.1±1.0mmol/l; P¼ 0.034).
A sensitivity assessment using a mixed-model repeated-
measures analysis also demonstrated an LSM±s.e. difference
of 2.2±0.6mmol/l between lixivaptan and placebo with
respect to changes in central sodium from baseline to day 7
(Po0.001).
The mean central serum sodium concentrations observed
over time are shown in Figure 3. The mean increase in serum
sodium concentrations was greater in the lixivaptan group
compared with the placebo group from day 2 until the end of
treatment. After discontinuation of lixivaptan on day 30,
mean serum sodium concentrations returned to near-
baseline levels by follow-up day 7. The change from baseline
in serum sodium concentration (average daily area under the
curve (AUC)) was significantly higher in the lixivaptan group
compared with the placebo group during the first 3 days of
treatment (LSM±s.e.: 3.3±0.4 vs. 1.7±0.5mmol/l, respec-
tively; P¼ 0.011) and throughout all 30 days of treatment
(6.6±0.7 vs. 4.7±0.7mmol/l, respectively; P¼ 0.043; Fig-
ure 4). The percentage of subjects achieving normalized
serum sodium concentrations was significantly higher with
lixivaptan compared with placebo (on day 7: 44.4% vs.
23.1%, respectively; P¼ 0.022). Time to first serum sodium
concentration X135mmol/l was significantly shorter in the
lixivaptan group than in the placebo group (P¼ 0.004;
Figure 5). Serum sodium normalization was achieved in over
50% of lixivaptan-treated subjects by day 4 of treatment. This
end point was not achieved until day 30 for the placebo-
control group, despite a greater use of fluid restriction.
As previously noted, fewer subjects in the lixivaptan group
(37.0%) were on fluid restriction at baseline compared with
subjects in the placebo group (65.4%). During the treatment
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period, this percentage did not change significantly from
baseline at any time point in either group (P¼ 0.064). Between
groups, the percentage of subjects on fluid restriction was
significantly lower in the lixivaptan group than in the placebo
group at every time point during the treatment period. The
percentage of subjects who experienced worsening of hypona-
tremia (see ‘Materials and Methods’ section) at any point
during the study did not differ significantly between groups
(53.7% in the lixivaptan group and 59.6% in the placebo
group; P¼ 0.545). Overall, 46.3% of subjects in the lixivaptan
group and 40.4% of subjects in the placebo group reported no
episodes of worsening hyponatremia.
No significant difference was observed between groups
with respect to changes from baseline to day 30 in the time
required to complete the Trail Making Test, Part B (TMT-B).
However, within the lixivaptan group, the time to complete
the test decreased significantly from baseline by a mean±s.d.
of 17.6±42.59 s (P¼ 0.013). No statistically significant
difference was observed between the lixivaptan and placebo
groups with respect to mean change in the Medical
Outcomes Study 6-Item Cognitive Function Scale (MOS-6)
score from baseline to day 30/early termination.
Safety
The total mean±s.d. duration of exposure to lixivaptan was
25.6±8.8 days (actual mean dose¼ 77.6mg); exposure to
placebo was 24.3±9.3 days (putative mean dose¼ 84.9mg).
The most common treatment-emergent adverse events have
been summarized in Table 2. Most events were of mild or
moderate severity. Treatment-emergent serious adverse
events were reported by eight (16%) subjects in the lixivaptan
group and by 15 (29%) subjects in the placebo group.
Adverse events led to discontinuation of study medication
in two subjects (hyponatremia and hypotension; each n¼ 1)
receiving lixivaptan and in six subjects (secondary adreno-
cortical insufficiency and hyponatremia, hyponatremia,
cognitive disorder and hyponatremia, polydipsia, vomiting,
and hypernatremia; each n¼ 1) receiving placebo. No
treatment-emergent adverse events led to death in subjects
who received lixivaptan (Table 2). In the placebo group,
cardiorespiratory arrest, acute cardiac failure, and chronic
obstructive pulmonary disease led to the death of one subject,
and bile duct cancer, neoplasm progression, and cardiores-
piratory arrest led to three deaths, respectively. Two of these
deaths occurred during treatment and the remaining two
occurred within the 30-day follow-up period. An additional
subject in the placebo group died from unknown causes more
than 30 days after discontinuation of the study drug.
Two (4.0%) lixivaptan subjects and three (5.9%) placebo
subjects had a rate of sodium correction considered rapid by
protocol-specified guidelines. During treatment, two (4.0%)
lixivaptan subjects and one (2.0%) placebo subject had a
central serum sodium level 4145mmol/l. None of these
subjects experienced neurological signs or symptoms con-
sistent with osmotic demyelination syndrome. No clinically
significant changes were observed with respect to vital signs,
electrocardiogram results, hematology, biochemistry, or
urinalysis parameters.
DISCUSSION
This international, multicenter, randomized, double-blind,
placebo-controlled study demonstrated that lixivaptan, an
oral vasopressin V2-receptor antagonist, safely and effectively
corrects serum sodium concentrations in hospitalized out-
patients with euvolemic hyponatremia. After 7 days of
treatment, lixivaptan resulted in a significantly greater
increase in serum sodium concentration relative to placebo,
meeting the primary end point of the trial, and this effect was
maintained throughout the study period. In addition, the
Table 2 | Treatment-emergent adverse events in X5% of
subjects and serious adverse events in either treatment
group
Treatment-emergent adverse event,
n (%)
Lixivaptan
(n=50)
Placebo
(n=51)
Any adverse event 35 (70) 37 (73)
Constipation 7 (14) 4 (8)
Dizziness 6 (12) 1 (2)
Insomnia 6 (12) 1 (2)
Nausea 5 (10) 3 (6)
Dry mouth 4 (8) 2 (4)
Asthenia 4 (8) 0
Vomiting 3 (6) 3 (6)
Headache 3 (6) 5 (10)
Back pain 3 (6) 2 (4)
Hypotension 3 (6) 2 (4)
Peripheral edema 3 (6) 2 (4)
Diarrhea 2 (4) 5 (10)
Urinary tract infection 2 (4) 8 (16)
Fatigue 2 (4) 3 (6)
Pyrexia 2 (4) 3 (6)
Hyponatremia 2 (4) 6 (12)
Hypertension 1 (2) 5 (10)
Cough 0 4 (8)
Any serious adverse event 8 (16) 15 (29)
Hyponatremia 2 (4) 4 (8)
Urinary tract infection 0 3 (6)
Cardiorespiratory arrest 0 2 (4)
Addison’s disease 1 (2) 0
Acute cardiac failure 1 (2) 1 (2)
Altered state of consciousness 0 1 (2)
Bile duct cancer 0 1 (2)
Bile duct stenosis 0 1 (2)
Chronic obstructive pulmonary disease 0 1 (2)
Cognitive disorder 0 1 (2)
Depression 0 1 (2)
Diarrhea 0 1 (2)
Dysuria 0 1 (2)
Herpes zoster infection 0 1 (2)
Humerus fracture 0 1 (2)
Hypotension 1 (2) 1 (2)
Increased blood sodium 1 (2) 0
Meningitis coccidioides 1 (2) 0
Neoplasm progression 0 1 (2)
Osteomyelitis 0 1 (2)
Secondary adrenocortical insufficiency 0 1 (2)
Vomiting 1 (2) 0
Serious adverse event leading to death 0 4 (8)
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proportion of subjects achieving normalization of serum
sodium concentrations after 7 days was significantly higher in
the lixivaptan group compared with the placebo group (44%
vs. 23%, respectively). After discontinuation of lixivaptan,
serum sodium concentrations decreased to near-baseline
levels within 7 days, confirming the chronic nature of
euvolemic hyponatremia and the therapeutic efficacy of
lixivaptan. It is noteworthy that a greater percentage of
subjects in the placebo group were on fluid restriction
compared with subjects in the lixivaptan group at baseline
(65.4% vs. 37.0%, respectively) and throughout the study
(end of study: 64.7% vs. 43.1%, respectively). The need for
less fluid restriction at baseline in lixivaptan patients might
indicate that urine concentration was lower in this group
and that they tolerated greater fluid intake. However, it is
difficult to estimate the impact of this possible con-
founding effect on the results of the study. Treatment with
lixivaptan resulted in a statistically significantly greater
increase in sodium serum concentration compared with
placebo despite the fact that more placebo subjects were
on fluid restriction. As fluid restriction may impair
quality of life, this difference may be of substantial clinical
relevance.
A larger-than-expected number of patients in both
treatment arms experienced worsening of hyponatremia
(defined as a reduction in sodium concentration
X3.0mEq/l). This finding is difficult to interpret and
may be related to a variety of factors, including a narrow
definition of worsening hyponatremia, a larger-than-
expected variability of central laboratory results, and patient
noncompliance with water restriction and/or medication.
No effects on cognition could be demonstrated in this trial.
The study was not adequately powered for this assessment
and further research is needed in larger populations.
Lixivaptan 25–100mg once daily was well tolerated and
demonstrated a favorable safety profile. The overall rate of
adverse events with lixivaptan was similar to that of placebo,
and most adverse events observed in the lixivaptan group
were of mild-to-moderate severity. In particular, the
incidence of serious adverse events was 16% with lixivaptan
compared with 29% with placebo, and no treatment-
emergent adverse events led to death in the lixivaptan group
(compared with four deaths following treatment-emergent
adverse events in the placebo group). The tolerability profile
of lixivaptan compares well with that observed with
tolvaptan, in which 16% of subjects treated in placebo-
controlled trials (N¼ 223) reported thirst as an adverse event
and 11.0% reported polyuria/pollakiuria.25
Lixivaptan dosage was titrated on the basis of serum
sodium concentrations in an inpatient setting for the
first 48–72 h before release of the subject to the outpatient
setting. The relatively low initial dose and careful titration
of lixivaptan produced a slow, measured rise in serum
sodium concentrations. A controlled increase in serum
sodium concentrations is important in patients with
chronic hyponatremia because cellular adaptation may occur,
increasing the risk for ODS if serum sodium levels are
corrected too rapidly.30 Current recommendations call for
sodium increases of no more than 12mmol/l in 24 h or no
more than 18mmol/l in 48 h, and prescribing information
for conivaptan and tolvaptan includes a warning for ODS
associated with too-rapid correction of hyponatremia
(412mmol/l per 24 h).3,24,25 No cases of ODS have been
reported with these agents and no cases were observed in this
study.
The pretreatment characteristics of subjects who partici-
pated in this study confirm the high incidence of symptoms
attributable to hyponatremia in a population often believed
to be ‘asymptomatic’. The most common symptoms observed
in the study population before treatment were fatigue (61%
of overall population), slowing down of mental faculties
(51%), and irritability (32%). Results from the recently
published population-based Rotterdam study of over 5000
elderly subjects4 indicate that hyponatremia (observed in
7.7% of subjects; n¼ 399) was associated with an increased
risk for vertebral and incident nonvertebral fractures; in
addition, the all-cause mortality rate was higher in the
hyponatremic population. The majority of subjects (54.7%)
in the LIBRA study were X65 years of age, and lixivaptan
demonstrated efficacy and safety in this elderly population at
risk for hyponatremia and its associated morbidity and
mortality. Limiting adverse events associated with the
mechanism of action of the drug (e.g., thirst and polyuria)
is also particularly important in this population, as
tolerability is more likely to affect compliance.
Another randomized, double-blind, placebo-controlled,
phase III study of lixivaptan in outpatients with euvolemic
hyponatremia (HARMONY)31 was also completed recently.
The HARMONY study did not require hospitalization of
subjects but allowed for initiation of therapy in an outpatient
setting in which sodium concentrations could be monitored
at baseline and at 8 h after each treatment. The subjects in
the current study had more restrictive requirements for
baseline hyponatremia than did those in the HARMONY
study, as the main eligibility criterion was a baseline serum
sodium level of o130mmol/l for LIBRA and o135mmol/l
for HARMONY. In addition, subjects in LIBRA received a
higher starting dose of lixivaptan compared with those in the
HARMONY study. HARMONY subjects with more severe
hyponatremia at baseline experienced numerically greater
increases in sodium levels with lixivaptan than did those
with lower baseline sodium levels. Results are also forth-
coming for the recently completed phase III study of
lixivaptan in hyponatremic subjects with chronic heart
failure (THE BALANCE).
In conclusion, with its favorable safety and efficacy profiles,
this oral formulation of lixivaptan, which provides an easily
titratable dosing regimen and reduces the need for fluid
restriction, may represent a relevant option in the manage-
ment of hyponatremia in SIADH. An open-label extension of
LIBRA is ongoing, the results of which will help define further
the role of lixivaptan in the treatment of hyponatremia.
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MATERIALS AND METHODS
Subjects
Eligible subjects were men and women aged X18 years with
euvolemic hyponatremia (serum sodium o130mmol/l) who were
hospitalized or willing to be admitted to a monitored setting for
study-drug initiation (approximately the first 48–72 h of treatment).
No limitations were imposed regarding symptoms attributable to
hyponatremia at baseline or with respect to the severity of serum
sodium concentration reduction. However, subjects with overt
symptoms of hyponatremia requiring immediate intervention (e.g.,
lethargy, coma, seizures) were excluded from the trial. Subjects with
other forms of hyponatremia, including acute or transient,
pseudohyponatremia, hypertonic, or secondary to hypothyroidism
or adrenal insufficiency, were excluded. Other key exclusion criteria
were as follows: psychogenic polydipsia; serum creatinine level
43.0mg/dl; uncontrolled diabetes mellitus (i.e., glycosylated
hemoglobin 49%); severe pulmonary arterial hypertension ex-
pected to deteriorate; established diagnosis of New York Heart
Association class III or IV heart failure; ST-segment elevation,
myocardial infarction within 30 days, or active myocardial ischemia
at enrollment; history of cerebral vascular accident within 30 days of
screening; significant neurological impairment; nephritic syndrome;
advanced liver disease or documented diagnosis of cirrhosis or
alcoholic hepatitis; urinary tract obstruction; or terminal illness.
Subjects receiving radiotherapy and/or chemotherapy within 2
weeks of randomization, or demeclocycline, lithium carbonate, urea,
or a vasopressin antagonist for hyponatremia within 7 days of
enrollment, were excluded from the study as well. Women who were
breastfeeding, pregnant, or planning to become pregnant were ineli-
gible. The LIBRA study protocol was approved by the Institutional
Review Board or Independent Ethics Committee at each participat-
ing site and was conducted in accordance with the the Declaration
of Helsinki Principles and the International Conference on
Harmonisation guidelines for Good Clinical Practice. All subjects
provided written informed consent to participate.
Study design
The LIBRA study (ClinicalTrials.gov. identifier: NCT00660959) was a
multicenter, randomized, double-blind, placebo-controlled, phase III
study conducted at 37 enrolling sites in six countries (United States,
Canada, Belgium, Germany, Poland, and India). The study consisted
of a screening period (1±1 day), a treatment period (including both
a titration phase and a treatment phase) of approximately 30 days,
and a follow-up period of approximately 30 days.
Screening procedures included a complete medical history and
assessment of baseline symptoms of hyponatremia. Subjects were
initially randomized 1:1 to receive lixivaptan 50mg or matched
placebo capsules once daily in the morning with or without food. The
subsequent dosage of lixivaptan was 25mg, 50mg, or 100mg as a
single, once-daily dose, titrated on the basis of serum sodium
concentrations. Dose adjustments were based on clinical response,
investigator judgment, and the following criteria: (1) for a serum
sodium increase o5mmol/l from the previous measurement (over at
least 24 h) ando135mmol/l, the dosage was increased; (2) for serum
sodium 4135 and p145mmol/l or a change X5mmol/l from the
previous measurement, the dosage was not changed; (3) for a serum
sodium increase at too great a rate (412mmol/l per 24h or
48mmol/l per 8 h) on the first day or a value 4145mmol/l, fluid
intake was adjusted, the dosage was decreased or withheld, and/or the
Medical Monitor was contacted for guidance on withdrawal of the
subject from the study. Investigators were instructed, when possible,
not to institute fluid restriction for at least the first 72 h of dosing
so that the rate and magnitude of serum sodium change related to
study drug could be determined. However, fluid restriction could
be initiated at the investigator’s discretion throughout the duration
of the study. The treatment phase (days 4–30) began at the time of
discharge from the hospital or monitored setting, ideally when an
optimal increase in serum sodium had been achieved on a stable
dose of study drug.
Follow-up began at treatment termination (or early discontinua-
tion) and included study visits 7±1 and 30±2 days after the last dose.
Study assessments
The primary study end point was change from baseline in serum
sodium concentration on day 7. Prespecified secondary end points
were change from baseline in serum sodium (average daily AUC) up
to day 30, percentage of subjects achieving normalized serum
sodium (X135 andp145mmol/l), percentage of subjects requiring
fluid restriction at any time during the treatment period, percentage
of subjects with worsening hyponatremia (i.e.,X3mmol/l reduction
in serum sodium concentration from the preceding measurement
with a value o135mmol/l) during double-blind therapy, and
change from baseline in recorded time to complete the TMT-B on
day 30. The MOS-6 on day 30 was a tertiary end point.
Baseline serum sodium and creatinine levels were assessed within
24 h before the first dose of study drug to confirm eligibility. Serum
sodium level was also assessed approximately 8 h after the first dose,
before dosing on days 2, 3, 4, 7, 14, and 30, and 7±1 and 30±2 days
after the last dose. Serum sodium concentrations were obtained
using local laboratories for safety assessment and titration purposes,
as well as a central laboratory. All reported serum sodium analyses,
including AUC, worsening of hyponatremia, and percentage
normalized, were performed using central laboratory values; these
analyses were repeated using local laboratory values for the purpose
of sensitivity analysis only. In addition to serum sodium, standard
hematology, biochemistry, and urinalysis were performed at each
visit. The TMT-B, which evaluates motor speed and visual attention
by asking subjects to draw lines alternating between numbers and
letters,32 and the MOS-6, a six-item, self-reported measure of
cognitive function adjusted to a 100-point scale, were administered
at baseline and at day 30 or during the early termination visit.
Physical examinations, vital sign assessments, 12-lead electro-
cardiogram assessments, and clinical laboratory analyses were
conducted at baseline and at regular intervals throughout the
treatment and follow-up periods. Adverse event data were collected
at each visit, beginning immediately after informed consent was
obtained until completion of the final posttreatment follow-up visit
or 30 days after the last dose of study medication in the case of an
early termination. Subjects could report adverse events to their study
investigator at any point during the study.
Statistical analysis
A sample size of 50 subjects per group was determined to have 80%
power to detect a difference in treatment means of 4.2mmol/l,
assuming a common s.d. of 7.422 using a two-group t-test with a
0.05 two-sided significance level.
Primary analyses were conducted on the intent-to-treat (ITT)
population, consisting of all randomized subjects, with imputation
of missing values. Secondary efficacy analyses were also performed
for a modified ITT population, which consisted of all randomized
subjects who received at least one dose of study medication and had
a baseline and at least one scheduled on-therapy assessment of
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serum sodium. The safety population comprised all randomized
subjects who received at least one dose of double-blind study
medication.
For the primary efficacy analysis, an analysis of covariance model
with treatment and pooled country as factors and baseline serum
sodium level as the covariate was used to analyze the ITT
population. Missing data were handled by the last observation
carried forward/next observation carried back imputation method.
Sensitivity analyses for the primary end point were carried out using
the baseline observation carried forward and mixed-effects model
repeated-measures methods, as well as by using observed values.
All secondary end points were analyzed for the ITT population
using last observation carried forward/next observation carried
back–based imputation as the primary analysis. Time-normalized
AUC of change from baseline to day 30 was summarized by treatment
group and analyzed using an analysis of covariance. The trapezoidal
rule was used to calculate the AUC, normalized to the last sodium
measurement on treatment and carried forward as the day 30 value
when a day 30 sodium measurement was not available. The percen-
tages of subjects achieving normalized serum sodium on day 7,
requiring fluid restriction, and experiencing worsening hyponatremia
were tabulated by treatment group and compared using a Cochran–
Mantel–Haenszel test controlling for pooled country. The change
from baseline in the recorded time to complete the TMT-B on day 30
was summarized by treatment group and analyzed using an analysis
of covariance with the same factors as the primary analysis and
the respective baseline value as the covariate. Summary statistics of
changes from baseline in safety variables were calculated. Adverse
events were coded using preferred terms of the Medical Dictionary for
Regulatory Activities, and incidences of the following were summar-
ized: treatment-emergent adverse events, potentially drug-related
adverse events, serious adverse events, adverse events that led to study
withdrawal, and those that led to death.
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